217 related articles for article (PubMed ID: 18953107)
21. Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert.
Engel T; Goñi-Oliver P; Lucas JJ; Avila J; Hernández F
J Neurochem; 2006 Dec; 99(6):1445-55. PubMed ID: 17059563
[TBL] [Abstract][Full Text] [Related]
22. Pivotal role of glycogen synthase kinase-3: A therapeutic target for Alzheimer's disease.
Maqbool M; Mobashir M; Hoda N
Eur J Med Chem; 2016 Jan; 107():63-81. PubMed ID: 26562543
[TBL] [Abstract][Full Text] [Related]
23. Propentofylline attenuates tau hyperphosphorylation in Alzheimer's Swedish mutant model Tg2576.
Chauhan NB; Siegel GJ; Feinstein DL
Neuropharmacology; 2005 Jan; 48(1):93-104. PubMed ID: 15617731
[TBL] [Abstract][Full Text] [Related]
24. Activation of Ras-ERK Signaling and GSK-3 by Amyloid Precursor Protein and Amyloid Beta Facilitates Neurodegeneration in Alzheimer's Disease.
Kirouac L; Rajic AJ; Cribbs DH; Padmanabhan J
eNeuro; 2017; 4(2):. PubMed ID: 28374012
[TBL] [Abstract][Full Text] [Related]
25. GSK-3 Inhibitors: A New Class of Drugs for Alzheimer's Disease Treatment.
Pal D; Mukherjee S; Song IH; Nimse SB
Curr Drug Targets; 2021; 22(15):1725-1737. PubMed ID: 33459229
[TBL] [Abstract][Full Text] [Related]
26. Probing novel 1-aza-9-oxafluorenes as selective GSK-3beta inhibitors.
Voigt B; Krug M; Schächtele C; Totzke F; Hilgeroth A
ChemMedChem; 2008 Jan; 3(1):120-6. PubMed ID: 18000938
[TBL] [Abstract][Full Text] [Related]
27. Roles of glycogen synthase kinase 3 in Alzheimer's disease.
Cai Z; Zhao Y; Zhao B
Curr Alzheimer Res; 2012 Sep; 9(7):864-79. PubMed ID: 22272620
[TBL] [Abstract][Full Text] [Related]
28. Flow cytometry-based method to analyze the change in Tau phosphorylation in a hGSK-3beta and hTau over-expressing EcR-293 cell line.
Kurko D; Boros A; Dezso P; Urbányi Z; Sárvári M; Nagy J; Szombathelyi Z; Szendrei GI
Neurochem Int; 2006 Apr; 48(5):374-82. PubMed ID: 16420965
[TBL] [Abstract][Full Text] [Related]
29. Newly developed glycogen synthase kinase-3 (GSK-3) inhibitors protect neuronal cells death in amyloid-beta induced cell model and in a transgenic mouse model of Alzheimer's disease.
Noh MY; Chun K; Kang BY; Kim H; Park JS; Lee HC; Kim YH; Ku S; Kim SH
Biochem Biophys Res Commun; 2013 May; 435(2):274-81. PubMed ID: 23632329
[TBL] [Abstract][Full Text] [Related]
30. Can lithium or valproate untie tangles in Alzheimer's disease?
Tariot PN; Aisen PS
J Clin Psychiatry; 2009 Jun; 70(6):919-21. PubMed ID: 19573485
[No Abstract] [Full Text] [Related]
31. Activation of glycogen synthase kinase-3 induces Alzheimer-like tau hyperphosphorylation in rat hippocampus slices in culture.
Li X; Lu F; Tian Q; Yang Y; Wang Q; Wang JZ
J Neural Transm (Vienna); 2006 Jan; 113(1):93-102. PubMed ID: 15959856
[TBL] [Abstract][Full Text] [Related]
32. Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain.
Pei JJ; Tanaka T; Tung YC; Braak E; Iqbal K; Grundke-Iqbal I
J Neuropathol Exp Neurol; 1997 Jan; 56(1):70-8. PubMed ID: 8990130
[TBL] [Abstract][Full Text] [Related]
33. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides.
Phiel CJ; Wilson CA; Lee VM; Klein PS
Nature; 2003 May; 423(6938):435-9. PubMed ID: 12761548
[TBL] [Abstract][Full Text] [Related]
34. Tea polyphenols as multi-target therapeutics for Alzheimer's disease: An in silico study.
Mazumder MK; Choudhury S
Med Hypotheses; 2019 Apr; 125():94-99. PubMed ID: 30902161
[TBL] [Abstract][Full Text] [Related]
35. Truncation and activation of GSK-3β by calpain I: a molecular mechanism links to tau hyperphosphorylation in Alzheimer's disease.
Jin N; Yin X; Yu D; Cao M; Gong CX; Iqbal K; Ding F; Gu X; Liu F
Sci Rep; 2015 Feb; 5():8187. PubMed ID: 25641096
[TBL] [Abstract][Full Text] [Related]
36. The participation of insulin-like growth factor-binding protein 3 released by astrocytes in the pathology of Alzheimer's disease.
Watanabe K; Uemura K; Asada M; Maesako M; Akiyama H; Shimohama S; Takahashi R; Kinoshita A
Mol Brain; 2015 Dec; 8(1):82. PubMed ID: 26637371
[TBL] [Abstract][Full Text] [Related]
37. Transgenic mouse models for Alzheimer's disease: the role of GSK-3B in combined amyloid and tau-pathology.
Muyllaert D; Terwel D; Borghgraef P; Devijver H; Dewachter I; Van Leuven F
Rev Neurol (Paris); 2006 Oct; 162(10):903-7. PubMed ID: 17028556
[TBL] [Abstract][Full Text] [Related]
38. Lithium down-regulates tau in cultured cortical neurons: a possible mechanism of neuroprotection.
Rametti A; Esclaire F; Yardin C; Cogné N; Terro F
Neurosci Lett; 2008 Mar; 434(1):93-8. PubMed ID: 18289787
[TBL] [Abstract][Full Text] [Related]
39. Cdk5: one of the links between senile plaques and neurofibrillary tangles?
Lee MS; Tsai LH
J Alzheimers Dis; 2003 Apr; 5(2):127-37. PubMed ID: 12719630
[TBL] [Abstract][Full Text] [Related]
40. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
